Tumor lymphangiogenesis and melanoma metastasis
Identifieur interne : 006D07 ( Main/Exploration ); précédent : 006D06; suivant : 006D08Tumor lymphangiogenesis and melanoma metastasis
Auteurs : Matthias Rinderknecht [Suisse] ; Michael Detmar [Suisse]Source :
- Journal of Cellular Physiology [ 0021-9541 ] ; 2008-08.
Abstract
Malignant melanomas of the skin primarily metastasize to lymph nodes, and the detection of sentinel lymph node metastases serves as an important prognostic parameter. There is now compelling evidence that melanomas can induce lymphangiogenesis (growth of lymphatic vessels), mainly at the tumor–stroma interface, and that the level of tumor lymphangiogenesis is correlated with the incidence of sentinel lymph node metastases and with disease‐free survival. Thus, tumor lymphangiogenesis can serve as a novel prognostic predictor in melanoma. Vascular endothelial growth factor (VEGF)‐C, released by melanoma cells and by tumor‐associated macrophages, likely represents the major lymphangiogenic factor in melanoma, although other members of the VEGF family might also be involved. The recent discovery that tumors can induce a premetastatic niche, by inducing lymphatic vessel growth in sentinel lymph nodes even before metastasis, and that lymph node lymphangiogenesis enhances metastatic spread, indicates that activated lymphatic vessels represent novel targets for the detection and/or therapy of melanoma metastases. J. Cell. Physiol. 216: 347–354, 2008. © 2008 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jcp.21494
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 006014
- to stream Istex, to step Curation: 006014
- to stream Istex, to step Checkpoint: 000F66
- to stream Main, to step Merge: 006E16
- to stream Main, to step Curation: 006D07
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumor lymphangiogenesis and melanoma metastasis</title><author><name sortKey="Rinderknecht, Matthias" sort="Rinderknecht, Matthias" uniqKey="Rinderknecht M" first="Matthias" last="Rinderknecht">Matthias Rinderknecht</name></author><author><name sortKey="Detmar, Michael" sort="Detmar, Michael" uniqKey="Detmar M" first="Michael" last="Detmar">Michael Detmar</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CCBD607FF98EB66F8D3F879DA817C1820A93508E</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/jcp.21494</idno><idno type="url">https://api.istex.fr/document/CCBD607FF98EB66F8D3F879DA817C1820A93508E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">006014</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">006014</idno><idno type="wicri:Area/Istex/Curation">006014</idno><idno type="wicri:Area/Istex/Checkpoint">000F66</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F66</idno><idno type="wicri:doubleKey">0021-9541:2008:Rinderknecht M:tumor:lymphangiogenesis:and</idno><idno type="wicri:Area/Main/Merge">006E16</idno><idno type="wicri:Area/Main/Curation">006D07</idno><idno type="wicri:Area/Main/Exploration">006D07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tumor lymphangiogenesis and melanoma metastasis</title><author><name sortKey="Rinderknecht, Matthias" sort="Rinderknecht, Matthias" uniqKey="Rinderknecht M" first="Matthias" last="Rinderknecht">Matthias Rinderknecht</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich</wicri:regionArea><wicri:noRegion>Zurich</wicri:noRegion></affiliation></author><author><name sortKey="Detmar, Michael" sort="Detmar, Michael" uniqKey="Detmar M" first="Michael" last="Detmar">Michael Detmar</name><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Zurich</wicri:regionArea><wicri:noRegion>Zurich</wicri:noRegion></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, ETH Zurich, Wolfgang Pauli‐Str. 10, HCI H303, CH‐8093 Zurich</wicri:regionArea><wicri:noRegion>CH‐8093 Zurich</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Cellular Physiology</title><title level="j" type="alt">JOURNAL OF CELLULAR PHYSIOLOGY</title><idno type="ISSN">0021-9541</idno><idno type="eISSN">1097-4652</idno><imprint><biblScope unit="vol">216</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="347">347</biblScope><biblScope unit="page" to="354">354</biblScope><biblScope unit="page-count">8</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-08">2008-08</date></imprint><idno type="ISSN">0021-9541</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0021-9541</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Malignant melanomas of the skin primarily metastasize to lymph nodes, and the detection of sentinel lymph node metastases serves as an important prognostic parameter. There is now compelling evidence that melanomas can induce lymphangiogenesis (growth of lymphatic vessels), mainly at the tumor–stroma interface, and that the level of tumor lymphangiogenesis is correlated with the incidence of sentinel lymph node metastases and with disease‐free survival. Thus, tumor lymphangiogenesis can serve as a novel prognostic predictor in melanoma. Vascular endothelial growth factor (VEGF)‐C, released by melanoma cells and by tumor‐associated macrophages, likely represents the major lymphangiogenic factor in melanoma, although other members of the VEGF family might also be involved. The recent discovery that tumors can induce a premetastatic niche, by inducing lymphatic vessel growth in sentinel lymph nodes even before metastasis, and that lymph node lymphangiogenesis enhances metastatic spread, indicates that activated lymphatic vessels represent novel targets for the detection and/or therapy of melanoma metastases. J. Cell. Physiol. 216: 347–354, 2008. © 2008 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Suisse</li></country></list><tree><country name="Suisse"><noRegion><name sortKey="Rinderknecht, Matthias" sort="Rinderknecht, Matthias" uniqKey="Rinderknecht M" first="Matthias" last="Rinderknecht">Matthias Rinderknecht</name></noRegion><name sortKey="Detmar, Michael" sort="Detmar, Michael" uniqKey="Detmar M" first="Michael" last="Detmar">Michael Detmar</name><name sortKey="Detmar, Michael" sort="Detmar, Michael" uniqKey="Detmar M" first="Michael" last="Detmar">Michael Detmar</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006D07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006D07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CCBD607FF98EB66F8D3F879DA817C1820A93508E
|texte= Tumor lymphangiogenesis and melanoma metastasis
}}
| This area was generated with Dilib version V0.6.31. |  |